Portal de Periódicos da CAPES

Side‐effects of treatments for locally advanced prostate cancer

2005; Wiley; Volume: 97; Issue: 1 Linguagem: Inglês

10.1111/j.1464-410x.2006.05865.x

1464-410X

Kevin O’Connor, John M. Fitzpatrick,

Bladder and Urothelial Cancer Treatments

BJU InternationalVolume 97, Issue 1 p. 22-28 Side-effects of treatments for locally advanced prostate cancer KEVIN M. O'CONNOR, Corresponding Author KEVIN M. O'CONNOR Department of Surgery, Mater Misericordiae University Hospital, University College Dublin, IrelandKevin M. O'Connor, Department of Surgery, Mater Misericordiae University Hospital, 47 Eccles Street, Dublin 7, Ireland. e-mail: [email protected]Search for more papers by this authorJOHN M. FITZPATRICK, JOHN M. FITZPATRICK Department of Surgery, Mater Misericordiae University Hospital, University College Dublin, IrelandSearch for more papers by this author KEVIN M. O'CONNOR, Corresponding Author KEVIN M. O'CONNOR Department of Surgery, Mater Misericordiae University Hospital, University College Dublin, IrelandKevin M. O'Connor, Department of Surgery, Mater Misericordiae University Hospital, 47 Eccles Street, Dublin 7, Ireland. e-mail: [email protected]Search for more papers by this authorJOHN M. FITZPATRICK, JOHN M. FITZPATRICK Department of Surgery, Mater Misericordiae University Hospital, University College Dublin, IrelandSearch for more papers by this author First published: 06 December 2005 https://doi.org/10.1111/j.1464-410X.2006.05865.xCitations: 21Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Oh WK, Kantoff PW. Treatment of locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 1999; 17: 3664– 75 2 Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003; 8: 259– 69 3 Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 1999; 35 (Suppl. 1): 23– 5 4 Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys 2005; 61: 1285– 90 5 Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467– 71 6 Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of PSA testing: 15-year outcome. BJU Int 2005; 95: 751– 6 7 Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166: 2208– 15 8 Iversen P. Orchidectomy and oestrogen therapy revisited. Eur Urol 1998; 34 (Suppl. 3): 7– 11 9 PCTCG. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355: 1491– 8 10 Schellhammer PF, Sharifi R, Block NL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997; 50: 330– 6 11 Sandow J. Clinical applications of LHRH and its analogues. Clin Endocrinol (Oxf) 1983; 18: 571– 92 12 Metz R, Namer M, Adenis L et al. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial. Am J Clin Oncol 1988; 11 (Suppl. 2): S112– 4 13 Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 2001; 87: 47– 56 14 Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001; 19: 72– 80 15 Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579– 82 16 Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison of 'Casodex' (bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447– 56 17 Moyad MA. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 2002; 59 (Suppl. 1): 20– 33 18 Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87: 3656– 61 19 Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154– 64 20 Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008– 12 21 Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742– 5 22 Bogdanos J, Karamanolakis D, Milathainakis C, Repousis P, Tsintavis A, Koutsilieris M. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res 2003; 23: 1757– 62 23 Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79: 933– 41 24 Green HJ, Pakenham KI, Headley BC et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002; 90: 427– 32 25 Cherrier MM, Asthana S, Plymate S et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001; 57: 80– 8 26 Green HJ, Pakenham KI, Headley BC, Gardiner RA. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 2004; 93: 975– 9 27 Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K and the Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865– 70 28 Widmark A, Fossa SD, Lundmo P et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61: 145– 51 29 Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology 1997; 50: 929– 33 30 Fitzpatrick JM, Kirby RS, Krane RJ, Adolfsson J, Newling DW, Goldstein I. Sexual dysfunction associated with the management of prostate cancer. Eur Urol 1998; 33: 513– 22 31 Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272– 6 32 Lawton CA, Won M, Pilepich MV et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21: 935– 9 33 Ataman F, Zurlo A, Artignan X et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer 2004; 40: 1674– 81 34 Zurlo A, Collette L, Van Tienhoven G et al. Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863. Eur Urol 2002; 42: 125– 32 35 Hanks GE, Pajak TF, Porter A et al. Radiation Therapy Oncology Group Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol 2003; 21: 3972– 8 36 Incrocci L, Slob AK, Levendag PC. Sexual (dys)function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 2002; 52: 681– 93 37 Pilepich MV, Krall JM, Al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616– 23 38 Borghede G, Hedelin H. Radiotherapy of localised prostate cancer. Analysis of late treatment complications. A prospective study. Radiother Oncol 1997; 43: 139– 46 39 Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol 2004; 171: 1132– 6 40 Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491– 500 41 Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8–12 years' follow-up. Int J Radiat Oncol Biol Phys 2002; 54: 427– 35 42 Pollack A, Zagars GK, Starkschall G et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097– 105 43 Valicenti RK, Winter K, Cox JD et al. RTOG 94–06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys 2003; 57: 614– 20 44 Liu M, Pickles T, Agranovich A et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 2004; 58: 59– 67 45 Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 3– 11 46 Sandler HM, McLaughlin PW, Ten Haken RK, Addison H, Forman J, Lichter A. A three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1995; 33: 797– 801 47 Huang EH, Pollack A, Levy L et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002; 54: 1314– 21 48 Zelefsky MJ, Fuks Z, Hunt M et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166: 876– 81 49 Martinez AA, Gustafson G, Gonzalez J et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 316– 27 50 Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005; 61: 1306– 16 51 Walsh PC. Radical retropubic prostatectomy with reduced morbidity: an anatomic approach. NCI Monogr 1988; 7: 133– 7 52 Ward JF, Zincke H. Radical prostatectomy for the patient with locally advanced prostate cancer. Curr Urol Rep 2003; 4: 196– 204 53 Davidson PJ, Van Den Ouden D, Schroeder FH. Radical prostatectomy: prospective assessment of mortality and morbidity. Eur Urol 1996; 29: 168– 73 54 Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002; 60 (Suppl. 1): 3– 11 55 Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502– 12 56 Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171: 709– 13 57 Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509– 16 Citing Literature Volume97, Issue1January 2006Pages 22-28 ReferencesRelatedInformation